Kolexia
Van-Hulst Sylvie Oncologie médicale
Van-Hulst Sylvie
Oncologie médicale
Hôpital Carémeau
Nîmes, France
45 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Carcinome pulmonaire à petites cellules Tumeurs du poumon Carcinome pulmonaire non à petites cellules Tumeurs du cerveau Carcinomes Tumeurs colorectales Métastase tumorale Carcinome transitionnel {{person.topmesh10.name}}

Collaborateurs

Voir plus
Ray Patrice
Ray Patrice
Hôpital Carémeau, Nîmes, France
Ducrocq Vincent
Ducrocq Vincent
Hôpital Carémeau, Nîmes, France
Rieux Cecile
Rieux Cecile
Hôpital Carémeau, Nîmes, France
Plouvier Nathalie
Plouvier Nathalie
Hôpital Carémeau, Nîmes, France

Industries

Voir plus
AstraZeneca
35 collaboration(s)
Dernière en 2023
Amgen
15 collaboration(s)
Dernière en 2023
Sanofi
12 collaboration(s)
Dernière en 2023
MSD
10 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
Adjuvant Chemotherapy in Patients With Intermediate or High Risk Stage I or Stage IIA Non-squamous Non-Small Cell Lung Cancer: A Randomized Prospective Trial of Adjuvant Chemotherapy in Patients With Completely Resected Stage I or IIA Non-Squamous Non-Small Cell Lung Cancer Identified as Intermediate or High Risk by a 14-Gene Prognostic Assay
Essai Clinique (Razor Genomics)   20 décembre 2023
NIRVANA-LUNG: PD-1 Inhibitor and Chemotherapy With Concurrent Irradiation at Varied Tumour Sites in Advanced Non-small Cell Lung Cancer
Essai Clinique (Unicancer)   11 décembre 2023
LBA62 Durvalumab after radiotherapy (RT) in patients with unresectable stage III NSCLC ineligible for chemotherapy (CT): Primary results from the DUART study
Abstract Book of the ESMO Congress 2023, 20 - 24 October 2023.   01 octobre 2023
Long-term effectiveness and treatment sequences in patients with extensive stage small cell lung cancer receiving atezolizumab plus chemotherapy: Results of the IFCT-1905 CLINATEZO real-world study.
Lung cancer (Amsterdam, Netherlands)   22 septembre 2023
3MO Comprehensive biomarkers (BMS) analysis to predict efficacy of PD1/L1 immune checkpoint inhibitors (ICIs) in combination with chemotherapy: A subgroup analysis of the precision immuno-oncology for advanced non-small cell lung cancer (pioneer) trial
Abstract Book of the ESMO Immuno-Oncology Congress 2022 7-9 December 2022   01 décembre 2022
Does Very Poor Performance Status Systematically Preclude Single Agent Anti-PD-1 Immunotherapy? A Multicenter Study of 35 Consecutive Patients.
Cancers   02 mars 2021
IFCT-1701 DICIPLE: A randomized phase III trial comparing continuation nivolumab-Ipilimumab doublet immunotherapy until progression versus observation in patients with PDL1-positive stage IV non-small cell lung cancer (NSCLC) after nivolumab-ipilimumab induction treatment
Abstract Book of the 44th ESMO Congress (ESMO 2019) 27 September – 1 October 2019, Barcelona, Spain   01 octobre 2019
Des ateliers piluliers en psychiatrie en amont des permissions de sortie : état des lieux du savoir et savoir-faire des patients
Le Pharmacien Hospitalier et Clinicien   01 décembre 2017
Results of the GETUG-AFU 19 trial: A randomized phase II study of dose dense methotrexate, vinblastine, doxorubicin, and cisplatin (dd-MVAC) with or without anti-epidermal growth factor receptor (EGF-R) monoclonal antibody panitumumab (PANI) in advanced transitional cell carcinoma (ATCC).
2017 Genitourinary Cancers Symposium   29 mars 2017
Is panitumumab monotherapy safe in metastatic colorectal cancer patients over 70 years old?
2015 Gastrointestinal Cancers Symposium   20 janvier 2015